(Circulation. 2000;102:3111.)
© 2000 American Heart Association, Inc.
Basic Science Reports |
Ischemia-Reperfusion Injury at the Microvascular Level
Treatment by Endothelin A–Selective Antagonist and Evaluation by Myocardial Contrast Echocardiography
Presented in part at the 72nd Scientific Sessions of the American Heart Association, Atlanta, Ga, November 7–10, 1999, and published in abstract form (Circulation. 1999;100[suppl I]:I-205). Award Winner Abstract of the 21st European Congress of Cardiology, Barcelona, Spain, August 28–September 1, 1999.
From the Division of Cardiovascular Medicine, University of California at San Diego (L.G., A.N.D.); Alliance Pharmaceutical Corp, San Diego (U.d.B., K.M.N., S.F.F.); Department of Pathology, Veterans Affairs Medical Center and University of California San Diego (P.L.W.); Knoll AG, Ludwigshafen, Germany (M.K.); and the Department of Cardiovascular and Neurological Science, University of Cagliari, Italy (S.I.). Dr Galiuto is currently associated with the Institute of Cardiology of the Catholic University of the Sacred Heart, Rome, Italy.
Correspondence to Sabino Iliceto, MD, Department of Cardiovascular and Neurological Science, University of Cagliari, Cagliari, Italy. E-mail iliccard{at}pacs.unica.it
Background—The purpose of this study was to verify whether endothelin A–antagonist administration at the time of coronary reperfusion preserves postischemic microvasculature and whether myocardial contrast echo (MCE) is able to detect pharmacologically induced changes in microvascular reflow.
Methods and Results—Twenty dogs underwent 90 minutes of LAD occlusion (OCC) followed by 180 minutes of reperfusion (RP). Five minutes before LAD reopening, an intravenous bolus (5 mg/kg) of LU 135252 was given in 10 dogs and vehicle in the remaining 10. At baseline (BSL), OCC, and 90 and 180 minutes of RP, microvascular flow (BF) was assessed by microspheres, and MCE was performed with intravenous echo contrast. MCE videointensity and BF were expressed as risk area/control ratio. Myocardial thickness of the risk area was calculated by 2D echo. No differences in BF between the 2 groups were observed at BSL, OCC, and 90 minutes of RP. At 180 minutes of RP, BF was decreased in controls (70±7.4% of BSL; P<0.005 versus BSL) and preserved in LU 135252–treated animals (89±4% of BSL; P=NS versus BSL; P<0.05 versus controls). Videointensity at MCE closely followed the changes in BF observed in both groups throughout the protocol. Myocardial thickness at 180 minutes of RP increased to 138.6±9.9% of BSL in controls and remained at 108.9±7.4% of BSL in treated dogs (P<0.05).
Conclusions—Endothelin A–antagonist treatment at the time of reperfusion significantly limited the progressive decrease in postischemic microvascular reflow and the increase in myocardial thickness. MCE allowed a reliable evaluation of pharmacologically induced changes in microvascular flow.
Key Words: myocardial infarction • ischemia • reperfusion • endothelin • contrast media
This article has been cited by other articles:
 |
|
 |
|
  M. I. Worthley, R. S. Kanani, Y.-H. Sun, Y. Sun, D. M. Goodhart, M. J. Curtis, and T. J. Anderson Effects of tetrahydrobiopterin on coronary vascular reactivity in atherosclerotic human coronary arteries Cardiovasc Res, December 1, 2007; 76(3): 539 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Apple, J. E. McLean, C. E. Squires, B. Schaeffer, J. A. Sample, R. L. Murphy, A. M. Deschamps, A. H. Leonardi, C. M. Allen, J. W. Hendrick, et al. Differential Effects of Protein Kinase C Isoform Activation in Endothelin-Mediated Myocyte Contractile Dysfunction With Cardioplegic Arrest and Reperfusion Ann. Thorac. Surg., August 1, 2006; 82(2): 664 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Niccoli, G. A. Lanza, S. Shaw, E. Romagnoli, D. Gioia, F. Burzotta, C. Trani, M. A. Mazzari, R. Mongiardo, M. De Vita, et al. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization Eur. Heart J., August 1, 2006; 27(15): 1793 - 1798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Korosoglou, A Hansen, R Bekeredjian, A Filusch, S Hardt, D Wolf, D Schellberg, H A Katus, and H Kuecherer Usefulness of myocardial parametric imaging to evaluate myocardial viability in experimental and in clinical studies Heart, March 1, 2006; 92(3): 350 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Galiuto Quantifying myocardial perfusion using contrast echocardiography Heart, February 1, 2005; 91(2): 133 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hansen, A. Kumar, D. Wolf, K. Frankenbergerova, A. Filusch, M.-L. Gross, S. Mueller, H. Katus, and H. Kuecherer Evaluation of cardioprotective effects of recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in myocardial ischemia-reperfusion injury by real-time myocardial contrast echocardiography J. Am. Coll. Cardiol., August 18, 2004; 44(4): 887 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Fujii, S. Tomita, T. Nakatani, S. Fukuhara, A. Hanatani, Y. Ohtsu, M. Ishida, C. Yutani, K. Miyatake, and S. Kitamura A novel application of myocardial contrast echocardiography to evaluate angiogenesis by autologous bone marrow cell transplantation in chronic ischemic pig model J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1299 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Galiuto Optimal therapeutic strategies in the setting of post-infarct no reflow: the need for a pathogenetic classification Heart, February 1, 2004; 90(2): 123 - 125. [Full Text] [PDF]
|
|
|
|
|
|
H. Kunichika, O. Ben-Yehuda, S. Lafitte, N. Kunichika, B. Peters, and A. N. DeMaria Effects of glycoprotein iib/iiia inhibition on microvascular flow after coronary reperfusion: A quantitative myocardial contrast echocardiography study J. Am. Coll. Cardiol., January 21, 2004; 43(2): 276 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Inagaki, H. S. Hahn, G. W. Dorn II, and D. Mochly-Rosen Additive Protection of the Ischemic Heart Ex Vivo by Combined Treatment With {delta}-Protein Kinase C Inhibitor and {epsilon}-Protein Kinase C Activator Circulation, August 19, 2003; 108(7): 869 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Basso, G. Thiene, M. Della Barbera, A. Angelini, M. Kirchengast, and S. Iliceto Endothelin A-receptor antagonist administration immediately after experimental myocardial infarction with reperfusion does not affect scar healing in dogs Cardiovasc Res, July 1, 2002; 55(1): 113 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Rezkalla and R. A. Kloner No-Reflow Phenomenon Circulation, February 5, 2002; 105(5): 656 - 662. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Pernow, A.T. Gonon, and A. Gourine The role of the endothelium for reperfusion injury Eur. Heart J. Suppl., June 1, 2001; 3(suppl_C): C22 - C27. [Abstract] [PDF]
|
|